News / Blog
May Holidays 2023 - Pay Attention!
Relumina tablets 40 mg for uterine myoma (Relugolix)
Product Code :
Availability : 10
General information on Japanese Relumina tablets 40 mg for uterine myoma (Relugolix)
Package details: 100 tablets
Manufacturer: ASKA Pharmaceutical Co.,Ltd, Japan
Active ingredient: relugolix (chemical formula C29H27F2N7O5S)
Medical effect: Relumina tablets are effective for the treatment of uterine myoma (uterine fibroids) and its following symptoms:
- lower abdominal pain,
- low back pain,
Contraindications and precautions: do not use in pregnant or breastfeeding women. Do not use in patients with undiagnosed abnormal genital bleeding.
Avoid pregnancy in a way other than taking hormone medicine while you are taking this medicine.
The maximum duration of medication is 6 months. If a patient takes this medicine for more than 6 months according to the consulting doctor's decision, the patient should receive bone mineral density tests regularly.
If an allergic reaction occurs, stop using the medication and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.
Dosage and administration of Relumina tablets 40 mg from Japan for uterine myoma (Relugolix)
For adults, take 1 tablet 1 time a day before meals. The first dose should be strictly taken from the first to fifth day of the menstrual cycle.
How effective are Relumina tablets 40 mg from Japan for uterine myoma (Relugolix)?
Relumina tablets contain relugolix, a gonadotropin-releasing hormone antagonist. They work by suppressing secretion of luteinizing hormone and follicle-stimulating hormone. By this, Relumina tablets reduce level of sex hormone such as estradiol and progesterone in the ovary. In average, the standard dosage of relugolix of 40 mg once per day suppresses estradiol levels to <20 pg/mL within 24 hours in premenopausal women.
Who should use Relumina tablets 40 mg from Japan?
Relumina tablets are effective for the treatment of uterine myoma (uterine fibroids) and such symptoms as menorrhagia, lower abdominal pain, low back pain and anemia. Clinical trials showed that relugolix combination achieved a 73.4% responder rate in the treatment of heavy menstrual bleeding associated with uterine fibroids compared with 18.9% in the placebo group. Also, relugolix demonstrated a statistically significant improvement in pain in 57.6% of women compared to 3.1% of women receiving placebo. Doctors particularly recommend the treatment with Relumina tablets for women with uterine fibroids who would refuse, postpone or are not candidates for surgery (F. Barra, M. Seca et al. Relugolix for the Treatment of Uterine Fibroids // Drugs of today (Barcelona, Spain). 2019, August, 55(8): 503-512).